Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details)

v3.19.1
Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
NCI - equity (deficit) - beginning of period  
Net loss attributable to NCI (204,072)
NCI - equity (deficit) - end of period (161,512)
Noncontrolling Interest [Member]    
NCI - equity (deficit) - beginning of period  
Investment in majority-owned subsidiary 1,812  
Payment of share Subscription Receivable  
Net loss attributable to NCI (204,072)  
Increase in additional paid-in capital of Lucid Diagnostics Inc. resulting from stock-based compensation recognized under the Lucid Diagnostics Inc 2018 Equity Plan 40,748  
NCI - equity (deficit) - end of period $ (161,512)